Join our daily newsletter At The Bell to receive exclusive market insights
- Microba Life Sciences (MAP) signs a distribution agreement with Luminary Health Centers to deliver a consumer microbiome test to consumers in the United States
- Luminary Health Centers will obtain non-exclusive distribution rights until 2027 to use Microba’s technology across its existing clinics in California
- The initial 12-month phase of the agreement is valued at US$458,000 (A$665,000) to Microba, with greater financial commitments on offer if agreed on by both parties
- Microba says the partnership will continue to expand Microba’s distribution base to deliver its testing technology to clinicians, patients and consumers
- MAP shares are up 13.51 per cent and trading at 42 cents at 11:57 am AEDT
Microba Life Sciences (MAP) has signed a distribution agreement with Luminary Health Centers to deliver a consumer microbiome test in the United States.
The microbiome test will be powered by Microba’s testing technology and delivered to consumers in the US.
Luminary Health Centers will receive non-exclusive distribution rights until 2027 to use the technology across its existing clinics.
Founded in 2020 in Salt Lake City, Utah, Luminary Health Centers considers itself a “first of its kind” nationwide network of speciality surgeons offering services to self-insured patients and their healthcare advocates. The centres offer genomic-driven health services across all its clinics throughout California.
The initial 12-month agreement is valued at US$458,000 (A$665,000) to Microba, with greater financial commitments on offer if agreed on by both parties.
Microba said the partnership would continue to expand its distribution base to deliver its testing technology to clinicians, patients and consumers.
MAP shares were up 13.51 per cent and trading at 42 cents at 11:57 am AEDT.
